Navigation Links
Undertreatment of cardiovascular disease in rheumatoid arthritis patients following a heart attack
Date:5/27/2011

Results of a study, involving 98,454 patients demonstrated that at 30 days following their first heart attack, RA patients were approximately 20% less likely to be prescribed standard MI treatments, such as statins and betablockers, compared to healthy patients. These finding remained relatively unchanged at 180 days, further highlighting differences between the two groups, with a high number being prescribed the current standards of care within the 180 day period (statins 80%, betablockers 82%, clopidogrel 70%, aspirin 79%) in general.

"Previous research has established that RA patients have an increased risk of cardiovascular disease (CVD). The results of our study suggest that CVD may be under treated in these patients, due to concerns regarding the use of multiple medications or patient compliance," said Dr. Jesper Lindhardsen of the Gentofte University Hospital in Copenhagen, Denmark. "Clinicians may find post-MI treatment in RA patients more complicated which would explain the lower propensity towards prescribing treatment; however this may be increasing the CVD burden seen in RA patients. Additional research is required in this area to establish whether further education is needed."

In the study, researchers identified 98,454 patients (39.4% female), who had suffered an MI for the first time, using the Danish National nationwide individual level registers, which included pharmacy records. Researchers examined 1,113 RA patient's prescriptions (62.5% female) between their first MI and 30 and 180 days following, allowing them to determine whether standard MI treatments had been prescribed or not. Odds ratios were calculated to determine the influence of RA, and were obtained using the statistical tool multivariate logistic regression modelling which included gender, age, co-morbidity and income.

Results of a separate study show that duration of RA doesn't further impact on CV risk over time

Results of one further study investigating the risk of CVD in RA patients, demonstrated that duration of RA did not increase the CVD risk over time. Previous studies have suggested that a number of factors may contribute to RA patients developing CVD such as chronic systemic inflammation or adverse effects associated with RA treatments. However the findings in this study showed no difference in the risk of CVD between patients who had suffered with RA for less or more than 10 years.


'/>"/>

Contact: Rory Berrie
rory.berrie@cohnwolfe.com
44-790-151-3297
European League Against Rheumatism
Source:Eurekalert

Related biology news :

1. Changing views about saturated fat and cardiovascular disease
2. Why do preterm deliveries pose cardiovascular risks for moms?
3. Penn Medicine researcher receives $6 million grant for cardiovascular disease study
4. Columbia University Medical Center announces 2010 Katz Prizes in cardiovascular research
5. Cardiovascular Innovation Institute researchers receive over $2 million grant from NIH
6. Significant weight-loss from surgery decreases risk for cardiovascular disease in women
7. EPA holds seminar on air pollution and cardiovascular disease
8. UH engineers to improve test for cardiovascular disease
9. CNIC and Banco Santander set up research project on early cardiovascular risk factors
10. New cancer therapy may fight cardiovascular disease
11. WPI receives $1.4 million from NIH for pioneering work on arterial plaque and cardiovascular disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/14/2016)... BioCatch ™, the global ... the appointment of Eyal Goldwerger as CEO. ... Goldwerger,s leadership appointment comes at a time of significant ... of its platform at several of the world,s largest ... unique cognitive and physiological factors, is a winner of ...
(Date:3/31/2016)... BOCA RATON, Florida , March 31, 2016 /PRNewswire/ ... LEGX ) ("LegacyXChange" or the "Company") ... presentation for potential users of its soon to be ... The video ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also ... by the use of DNA technology to an industry ...
(Date:3/29/2016)... BOCA RATON, Florida , March 29, 2016 /PRNewswire/ ... ("LegacyXChange" or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect ... Synthetic DNA in ink used in a variety of ... preventing theft. Buyers of originally created collectibles from athletes ... authenticity through forensic analysis of the DNA. ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , the leading software as ... Clinical Reach Virtual Patient Encounter CONSULT module which enables both audio and video ... trial team. , Using the CONSULT module, patients and physicians can schedule a face ...
(Date:6/27/2016)... --  Ginkgo Bioworks , a leading organism design ... awarded as one of the World Economic Forum,s ... innovative companies. Ginkgo Bioworks is engineering biology to ... in the nutrition, health and consumer goods sectors. ... including Fortune 500 companies to design microbes for ...
(Date:6/24/2016)... ... , ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical ... mesothelioma. Their findings are the subject of a new article on the Surviving Mesothelioma ... in the blood, lung fluid or tissue of mesothelioma patients that can help point ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
Breaking Biology Technology: